Search Patents
  • Glucose-responsive insulin conjugates
    Patent number: 9889205
    Abstract: Insulin conjugates comprising an insulin molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein the saccharide for at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: February 13, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Lin Yan, Pei Huo
  • Rubber stopper separator
    Patent number: 6220450
    Abstract: A device to separate rubber stoppers that have adhered together, typically as a result of sterilization. The device contains a hopper, a pair of rollers and a mechanism to turn the rollers. The rollers are hexagonal-shaped and each face has a scalloped concavity. The adhering stoppers are gravity-fed into the rollers from the hopper, where they are compressed and a shearing force is applied to separate the adherent stoppers. The separated stoppers are then collected for further processing.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: April 24, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Kristian N. Weeder, Gordon D. Deacon
  • Spirocyclic heterocyclic compounds useful as HIV integrase inhibitors
    Patent number: 10221186
    Abstract: The present invention relates to Spirocyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, X, Y, R1, R2 and R4 are as defined herein. The present invention also relates to compositions comprising at least one Spirocyclic Heterocycle Compound, and methods of using the Spirocyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: March 5, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mark W. Embrey, Thomas H. Graham, Izzat T. Raheem, John D. Schreier, Sherman T. Waddell, John S. Wai, Lihong Hu, Xuanjia Peng
  • Imidazo-triazine derivatives as ligands for GABA receptors
    Patent number: 6617326
    Abstract: A class of 7-phenylimidazo[1,2-b][1,2,4]triazine derivatives, substituted at the meta position of the phenyl ring by a (cyano)(fluoro)phenyl moiety, being selective ligands for GABAA receptors, in particular having good affinity for the &agr;2 and/or &agr;3 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety and convulsions.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: September 9, 2003
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: William Robert Carling, David James Hallett, Michael Geoffrey Neil Russell, Leslie Joseph Street
  • Effect pigments
    Patent number: 11479681
    Abstract: Effect pigments based on Al2O3 flakes with high weather resistance and less photoactivity and to their use thereof in paints, industrial coatings, automotive coatings, printing inks, cosmetic formulations. The effect pigments have a ratio of the amount by weight of Al2O3 of the Al2O3 flake and the amount by weight of the metal oxide(s) of the coating layer(s) in the range of from 27:73 to 83:17 based on the total weight of the effect pigment.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: October 25, 2022
    Assignee: Merck Patent GmbH
    Inventors: Sabine Schoen, Michael Jungnitz, Stefan Schlueter, Kirsten Fritsche, Carsten Plueg, Stephanie Andes, Ulrich Schoenefeld
  • Process of preparing regioregular polymers
    Patent number: 8221652
    Abstract: The invention relates to a process of preparing regioregular polymers, in particular head-to-tail (HT) poly-(3-substituted) thiophenes or selenophenes with high regioregularity and defined molecular weight, to novel polymers prepared by this process, to the use of the novel polymers as semiconductors or charge transport materials in optical, electrooptical or electronic devices including field effect transistors (FETs), electroluminescent, photovoltaic and sensor devices, and to FETs and other semiconducting components or materials comprising the novel polymers.
    Type: Grant
    Filed: December 10, 2007
    Date of Patent: July 17, 2012
    Assignee: Merck Patent GmbH
    Inventors: Timo Hoffart, Birgit Falk, Iain McCulloch, Weimin Zhang, Martin Heeney
  • Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases
    Patent number: 10899788
    Abstract: The present invention relates to Cyclic Phosphate Substituted Nucleoside Compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein in A, B, R1, R2, R3, Q and V are as defined herein. The present invention also relates to compositions comprising a Cyclic Phosphate Substituted Nucleoside Compound, and methods of using the Cyclic Phosphate Substituted Nucleoside Compounds for treating or preventing HCV infection in a patient.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: January 26, 2021
    Assignees: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLC
    Inventors: Stephane Bogen, David Dukhan, Guillaume Brandt, Claire Pierra Rouviere, Cyril B. Dousson, Francois-Rene Alexandre
  • Platelet-shaped titanium dioxide pigment
    Patent number: 5858078
    Abstract: Plateletlike, substrate-free titanium dioxide pigment obtainable by solidifying an aqueous solution of a thermally hydrolyzable titanium compound on a continuous belt, detaching the resulting layer, coating the resulting titanium dioxide platelets, with or without drying in between, with further titanium dioxide by a wet method, and separating off, drying and calcining the material obtained.
    Type: Grant
    Filed: January 9, 1998
    Date of Patent: January 12, 1999
    Assignee: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventors: Stefanie Andes, Gerd Bauer, Gunter Brenner, Dieter Bruckner, Andrea Heyland, Matthias Kuntz, Karl Osterried, Gerhard Pfaff, Michael Schmelz
  • Bacterial toxoids and gram-negative immune globulin therefrom
    Patent number: 4488991
    Abstract: ADP-Ribosylating toxins are rendered enzymatically inactive by reactions with photolabile affinity reagents. The toxoids retain the antigenic and immunogenic properties of the original toxins. These bacterial toxoids can be used as immunogens to protect against the specific disease that the precursor toxins cause or, in the case of P. aeruginosa, the toxoid can be used in combination with E. coli J-5 vaccine to protect against gram-negative bacteremia in general.
    Type: Grant
    Filed: October 26, 1983
    Date of Patent: December 18, 1984
    Assignee: Merck & Co., Inc.
    Inventors: Richard L. Tolman, Stephen Marburg, Lynn T. Callahan, III
  • Inhibitors of the renal outer medullary potassium channel
    Patent number: 9765074
    Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: September 19, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Alexander Pasternak, Fa-Xiang Ding, Shuzhi Dong, Dipshikha Biswas, Haifeng Tang, Jinlong Jiang, Cangming Yang, Xin Gu
  • Single stage avian embryo culture process
    Patent number: 5258307
    Abstract: A novel single stage culture system for avian embryos is disclosed. Premature eggs consisting of about 32 to about 100 cells are collected shortly after ovulation and prepared for culture. The eggs are incubated in a potassium rich bicarbonate solution and the contents of the eggs are transferred to recipient eggshells. The open end of the eggshell is closed and the embryos are turned and incubated in an oxygen enriched atmosphere for about 3-4 days. For the final incubation period the eggs are incubated in an upright position and rocked hourly.
    Type: Grant
    Filed: September 17, 1990
    Date of Patent: November 2, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Kenneth Simkiss, Roy G. Smith
  • 6-Bromocholesterol derivatives
    Patent number: 4430321
    Abstract: Novel 6-bromo derivatives of cholesterol have the formula ##STR1## Such compounds are prepared from the known 6-iodocholesterol by treatment with cuprous bromide.These compounds, labelled with radioisotopes of Br-82 or Br-77, are localized in the adrenal, mammary and ovary tissue of female mammals and in the adrenal or prostate tissue of males when administered to such individuals. This provides a method for imaging adrenal, ovary or prostate tissue which is superior to use of the prior art 6-iodo-cholesterol.
    Type: Grant
    Filed: January 15, 1982
    Date of Patent: February 7, 1984
    Assignee: Merck Frosst Canada Inc.
    Inventors: Richard J. Flanagan, Leonard I. Wiebe
  • Macrocyclic Tertiary Amine Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
    Publication number: 20080269302
    Abstract: The present invention is directed to macrocyclic tertiary amine compounds represented by general formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: November 14, 2005
    Publication date: October 30, 2008
    Applicant: MERCK & CO., INC.
    Inventors: Philippe G. Nantermet, Hemaka A. Rajapakse, Harold G. Selnick, Stacey Lindsley, Keith P. Moore, Shawn J. Stachel
  • Piperazine derivatives
    Patent number: 6251908
    Abstract: Piperazine derivatives of the formula I in which R1, m, k and R2 have the meanings indicated in claim 1, are potent 5-HT1A agonists and exhibit 5-HT-reuptake-inhibiting actions and are suitable for the treatment and prophylaxis of anxiety states, depression, schizophrenia, obsessions, tardive dyskinesias, learning disorders, age-dependent memory disorders, for positively affecting obsessive-compulsive disorder, and also for the treatment and for the control of the sequelae of cerebral infarcts such as stroke and cerebral ischaemias.
    Type: Grant
    Filed: April 3, 2000
    Date of Patent: June 26, 2001
    Assignee: Merck Patent Gesellschaft mit beschraenkter Haftung
    Inventors: Henning Böttcher, Gerd Bartoszyk, Hartmut Greiner, Christoph Seyfried
  • Liquid crystalline medium
    Patent number: 10982150
    Abstract: The present invention relates to liquid crystalline media comprising one or more naphthothiadiazol derivatives of formula I, in which R11, R12, A11, A12, A21, A22, Z11, Z12, Z21, Z22, W, X11, X12, L, r, s and t have the meanings indicated in claim 1, to the use of such liquid crystal media for optical, electro-optical and electronic purposes, in particular in devices for regulating the passage of energy from an outside space into an inside space, for example in windows.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: April 20, 2021
    Assignee: Merck Patent GmbH
    Inventors: Peer Kirsch, Rene Lutz, Michael Junge, Ursula Patwal
  • Ethyldiamine orexin receptor antagonists
    Patent number: 10011595
    Abstract: The present invention is directed to ethyldiamne compounds which are antagonists of orexin receptors. Such compounds are of the general structural formula I: The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: July 3, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ronald M. Kim, Scott D. Kuduk, Nigel Liverton, Gang Zhou
  • LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME AND COMPOUNDS
    Publication number: 20220267676
    Abstract: The invention relates to a liquid-crystalline medium having a nematic phase comprising one or more compounds of formula X wherein the parameters have the meaning given in the text, to the use thereof in an electro-optical display, particularly in an active-matrix display based on the IPS or FFS effect, to displays of this type which contain a liquid-crystalline medium of this type and to the use of the compounds of formula X for improvement of the transmission and/or response times of a liquid-crystalline medium which comprises one or more additional mesogenic compounds, as well as to the compounds of formula X.
    Type: Application
    Filed: July 2, 2020
    Publication date: August 25, 2022
    Applicant: MERCK PATENT GMBH
    Inventors: Atsutaka MANABE, Constanze BROCKE, Brigitte SCHULER
  • BIS-QUARTERNARY CINCHONA ALKALOID SALTS AS ASYMMETRIC PHASE TRANSFER CATALYSTS
    Publication number: 20150031891
    Abstract: The invention is directed to novel bis-quarternary cinchona alkaloid salts and the use of bis-quarternary cinchona alkaloid salts in asymmetric phase transfer catalysis. The present invention is directed to novel bis-quarternary cinchona alkaloid salts and the use of bis-quarternary cinchona alkaloid salts in asymmetric phase transfer catalysis. On certain substrates and under specific reaction conditions, the inventors have discovered that the use of bis-quarternary cinchona alkaloid salts in asymmetric phase transfer catalysis surprisingly provides for a more active and efficient process as compared to mono-quarternary catalysts.
    Type: Application
    Filed: March 13, 2013
    Publication date: January 29, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Bangping Xiang, Nobuyoshi Yasuda
  • Insect poison allergens with reduced IgE reactivity and method for producing the same
    Patent number: 8048424
    Abstract: The invention relates to recombinant insect poison allergens and to a specific method for producing them. Said allergens can be varied according to whether they are produced using folds (conformations) that are identical or different to those that occur naturally. The proteins with folds that do not occur naturally have a reduced IgE reactivity or allergenity and can therefore be used as therapeutic agents in the immunotherapy of allergies.
    Type: Grant
    Filed: August 9, 2007
    Date of Patent: November 1, 2011
    Assignee: Merck Patent GmbH
    Inventors: Roland Suck, Oliver Cromwell, Helmut Fiebig
  • Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
    Patent number: 9643982
    Abstract: The present invention relates to Fused Tricyclic Heterocycle Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R8, A, X and n are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Heterocycle Derivative, and methods of using the Fused Tricyclic Heterocycle Derivatives for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: May 9, 2017
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Paul J. Coleman, Timothy J. Hartingh, Izzat T. Raheem, John Schreier, John Sisko, John Wai, Thomas H. Graham, Lihong Hu, Xuanjia Peng
Narrow Results

Filter by US Classification